Beta 3 Adrenoreceptor Agonist for the Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia: A Systematic Review
Tae Wook Kang, Su Jin Kim, Myung Ha Kim, Jae Hung Jung
Int Neurourol J. 2021;25(3):182-191.   Published online 2021 Sep 30
Citations to this article as recorded by
  Crossref logo
Risks and side effects in the medical management of benign prostatic hyperplasia
Abdulghafour Halawani, Ryan Paterson, Tianshuang Zhong, Katie Du, Runhan Ren, Connor M. Forbes
Prostate International.2024; 12(2): 57.     CrossRef
Inside the Biology of the β3-Adrenoceptor
Amada Pasha, Annalisa Tondo, Claudio Favre, Maura Calvani
Biomolecules.2024; 14(2): 159.     CrossRef
Novel pharmacotherapeutic avenues for bladder storage dysfunction in men
Kang Jun Cho, Joon Chul Kim
Expert Opinion on Pharmacotherapy.2024; 25(5): 585.     CrossRef
Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms – A Multicenter, Randomized Study
Chih-Chieh Lin, Hann-Chorng Kuo, Jian-Ri Li, Yao-Chi Chuang
International Neurourology Journal.2023; 27(3): 182.     CrossRef
Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review
Collyn O'Quin, Kathryn L White, John R Campbell, Sarah H Myers, Shilpadevi Patil, Debbie Chandler, Shahab Ahmadzadeh, Giustino Varrassi, Sahar Shekoohi, Alan D Kaye
Cureus.2023;[Epub]     CrossRef
Lower Urinary Tract Symptoms With a View Beyond the Bladder and Prostate
Su Jin Kim
International Neurourology Journal.2022; 26(2): 85.     CrossRef